30 closest matches · ranked by relevance
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Systemic Mastocytosis
Primary: Number of Participants With Objective Response — 0 Participants
Advanced Systemic Mastocytosis · Aggressive Systemic Mastocytosis · Systemic Mastocytosis With an Associated Hematologic Neoplasm
Primary: Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on…
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
Indolent Systemic Mastocytosis
Primary: Percent Change in Quality of Life (QoL) Using Mastocytosis Quality of Life Questionnaire (MC-QoL) — 38.98; 33.02 percentage of change in quality of life — p=0.7740
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 6 participants
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Myelofibrosis · Chronic Myelomonocytic Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Polycythemia Vera · Thrombocythemia
Primary: Number of Participants With Best Overall Response — 0; 3; 6 Participants
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria — 10 percentage of participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants
Multiple Myeloma
Primary: Assessment of Safety of recMAGE-A3 + AS15 — 13; 8; 4; 0 participants
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Acute Myelogenous Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Myelodysplastic Syndromes (MDS)
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Participants
Alveolitis · Systemic Sclerosis
Primary: Treatment-related Adverse Events — 5 participants
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants